Scribe Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $174.2 million following its successful upsized IPO. The company is advancing its Phase 1 clinical trial for STX-1150, an epigenetic silencing therapy for LDL-C lowering, with initial data expected in the first half of 2027.
“This is a period of continued execution for Scribe, marked by the successful completion of our IPO and expansion of our collaboration with Sanofi to include the epigenetic silencing technology. Together, these milestones strengthen our foundation as we work to translate the potential of our technologies into meaningful medicines for patients.”
Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe Therapeutics
ProMIS Neurosciences reported a significant increase in cash to $44.1 million as of September 30, 2026, compared to $6.1 million at the end of 2025, primarily driven by financing activities that increased additional paid-in capital. The company's accumulated deficit grew to $158.5 million, reflecting ongoing research and development costs, while total shareholders' equity improved to a positive $41.8 million.
Crown Crafts reported second quarter fiscal 2027 results, with net income increasing to $1.3 million despite a decline in net sales to $19.0 million. The company achieved a significant gross margin expansion to 32.0%, driven by profitability initiatives and tariff refunds, and declared a quarterly dividend of $0.03 per share.
Term
Q2 2027
“We continue to execute well on our profitability initiatives with meaningful improvement this quarter in our gross profit, marketing and administrative expenses, and year-to-date operating cash flow.”
Olivia Elliott, President and Chief Executive Officer
“Our stronger profitability reflects our continued initiatives around efficiency and profitability, and our talented team is simultaneously focused on the development of additional higher-margin products and sales channels to grow both sales and profitability in the quarters ahead.”
Olivia Elliott, President and Chief Executive Officer
4D Molecular Therapeutics is a clinical-stage genetic medicine company reporting 56,379,402 shares of common stock outstanding as of November 9, 2026. The company continues to incur significant net losses and requires substantial additional capital to fund the development of its lead AAV product candidates, including 4D-150 and 4D-175.
AEVEX Corp. filed its 10-Q for the period ending September 30, 2026, highlighting the recent acquisition of Maritime Applied Physics Corporation (BlackSea) and its ongoing integration. The company continues to operate as a non-accelerated filer and emerging growth company following its April 2026 initial public offering.
GCT Semiconductor reported total net revenues of $3.96 million for the nine months ended September 30, 2026, an increase from $2.11 million in the prior year period. Despite the revenue growth, the company incurred a net loss of $37.63 million for the period, driven by high operating expenses and a significant $9.23 million loss from the change in fair value of common stock warrant liabilities.
Electra Therapeutics is a clinical-stage biotechnology company focused on SIRP-targeted therapies, specifically its lead candidates ipsoprubart and ELA822. As of November 2026, the company remains pre-revenue with significant operating losses and expects to require substantial additional capital to fund its research and development programs.
Atrium Therapeutics reported a net loss of $41.1 million for the nine months ended September 30, 2026, compared to $20.4 million in the prior year period, driven by a significant increase in general and administrative expenses following its spin-off. The company ended the quarter with $232.1 million in cash, cash equivalents, and short-term investments, bolstered by a $313.4 million transfer from its former parent company.
U.S. Global Investors reported its first quarter fiscal 2027 results, achieving 18% revenue growth to $2.7 million and returning to operating profitability. The company saw a 14% year-over-year increase in average assets under management to $1.6 billion, driven largely by a 45% surge in gold and precious metals strategies.
Term
Q1 2027
“Gold miners continued to draw investor interest during the quarter, and that showed up in our asset levels. Average assets in our gold strategies are up more than 45% from a year ago. We believe disciplined, actively managed exposure to high-quality miners remains an important part of a diversified portfolio, and we’re pleased that more investors appear to agree.”
Frank Holmes, CEO and Chief Investment Officer
“Defense is no longer defined just by aircraft and ships. It’s increasingly being reshaped by artificial intelligence (AI), autonomous systems and cybersecurity. As governments around the world direct more spending toward national security, we believe WAR, our actively managed Smart Beta 2.0 ETF, gives investors targeted exposure to the companies driving that transformation.”
MultiSensor AI Holdings reported a net loss of $1.95 million for the quarter ended September 30, 2026, a slight increase from the $1.68 million loss in the prior year period. While nine-month revenue grew to $4.81 million from $4.16 million, the company continues to experience operating losses and negative cash flow from operations as it expands its SaaS capabilities and condition intelligence platform.
ProMIS Neurosciences reported Q3 2026 financial results, ending the period with $44.1 million in cash which is expected to fund operations through 2027. The company reaffirmed that topline data from its Phase 1b PRECISE-AD trial of PMN310 in Alzheimer’s disease remains on track for the first quarter of 2027.
Term
Q3 2026
“The third quarter of 2026 has been productive for ProMIS, following encouraging interim data from our Phase 1b PRECISE-AD trial in Alzheimer’s disease (AD). Based on data generated to date, we continue to believe PMN310 offers a differentiated approach by selectively targeting the most toxic and destructive form of amyloid-beta, the oligomers.”
Neil Warma, President and Chief Executive Officer
“With PRECISE-AD closing out its final stage of patient visits, we look forward to reporting topline data in the first quarter of 2027, which will include safety, biomarker and clinical efficacy measures.”
Alumis Inc. reported total assets of $488.7 million as of September 30, 2026, supported by a significant increase in marketable securities following its IPO. The company is focused on the development of envudeucitinib (envu) for plaque psoriasis, with plans to submit a New Drug Application by the end of 2026.
Park Dental Partners reported third quarter 2026 revenue of $64.9 million, a 6% increase year-over-year driven by reimbursement trends and acquisitions. Net income rose 36.1% to $1.7 million, although diluted EPS decreased to $0.27 compared to $0.72 in the prior-year period. The company also highlighted the completion of the Village Family transaction, expanding its network into a fourth state.
Term
Q3 2026
“Third-quarter revenue increased 6%, supported by same-practice growth, an expanding affiliated doctor base and contributions from recently acquired practices. We have made meaningful progress adding clinical capacity and strengthening our platform, and our focus now is converting that capacity and revenue growth into improved productivity and stronger earnings performance.”
Pete Swenson, Chief Executive Officer and Chair of the Board of Directors
“The completion of the Village Family transaction represents an important step in our growth strategy and extends our affiliated practice network into a fourth state. We remain focused on disciplined integration, supporting our affiliated practices and executing against the opportunities already within our business.”
Pete Swenson, Chief Executive Officer and Chair of the Board of Directors
Carlyle Private Equity Partners Fund, L.P. reported total assets of $477.3 million as of September 30, 2026, a significant increase from $59.0 million at the end of 2025. The fund's investment portfolio grew to a fair value of $280.4 million, supported by substantial cash and cash equivalents of $194.2 million.
ProKidney Corp. reported third quarter 2026 financial results, ending the period with $141.9 million in cash and marketable securities to fund operations into mid-2027. The company remains on track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint topline results in Q2 2027. R&D expenses increased to $40.8 million, driven by clinical study and manufacturing costs for the ongoing rilparencel program.
Term
Q3 2026
“The third quarter marked continued progress for ProKidney, with PROACT 1 advancing toward full enrollment and our pivotal eGFR slope topline readout remaining on track for the second quarter of 2027. The data presented at Kidney Week further build the mechanistic and clinical evidence supporting rilparencel and provide a more cohesive picture of how it may stabilize kidney function. Together, these advances reinforce our confidence as we approach this important Phase 3 readout and continue our mission to transform the treatment of advanced CKD.”
Dragonfly Energy reported Q3 2026 net sales of $12.2 million, down 23.8% year-over-year due to softness in the RV market, though heavy-duty trucking revenue more than doubled sequentially. The company completed the acquisition of the Dakota Lithium brand during the quarter and expects to reach approximately breakeven Adjusted EBITDA in Q4 2026.
Term
Q3 2026
“Third quarter heavy-duty trucking revenue more than doubled sequentially to $1.3 million, in line with our August outlook, driven by expanding commercial fleet adoption. For the first time, we received orders from fleets moving directly into commercial deployment without a pilot program, reflecting the credibility we have established through years of field validation.”
Prairie Operating Co. reported a significant increase in revenues to $311.8 million for the nine months ended September 30, 2026, compared to $158.6 million in the prior year. However, the company incurred a net loss of $92.6 million for the period, driven largely by a $266.2 million loss on derivatives and increased operating expenses.
Electra Therapeutics reported third quarter 2026 financial results and provided updates on its SIRP-targeting portfolio, including the advancement of ipsoprubart in a global registrational program for sHLH. The company recently completed a $350 million IPO to fund its clinical pipeline, with several data readouts and enrollment milestones expected throughout 2027.
“Our recent IPO positions Electra to build on our first-mover advantage in SIRP-targeted precision immune cell depletion. Our deep expertise in SIRP biology and proprietary library of SIRP-targeting antibodies enable us to selectively address distinct pathogenic immune cell populations, creating therapeutic optionality across immune-mediated diseases and cancer.”
Kathy Dong, PharmD, MBA, President and Chief Executive Officer
CytoSorbents reported Q3 2026 financial results, highlighting the achievement of operating cash flow breakeven (excluding restructuring payments). Revenue grew 3% to $9.7 million, while operating loss improved by 59% to $1.2 million due to disciplined cost management and improved gross margins.
Term
Q3 2026
“The third quarter marked an important financial milestone for CytoSorbents as we achieved our goal of operating cash flow breakeven, excluding restructuring-related payments. This achievement reflects a year of disciplined execution and meaningful improvements in our underlying business.”
Fulcrum Therapeutics is currently pursuing a merger with Slate Medicines, Inc. while undergoing significant restructuring, including the cessation of clinical development for pociredir and a workforce reduction. The company reported a net loss of $56.0 million for the nine months ended September 30, 2026, and currently has no product candidates in active clinical development.
System1, Inc. reported its financial results for the third quarter ended September 30, 2026, disclosing revenue of $25.95 million. The company recorded a significant net loss of $51.28 million for the quarter, impacted by a $63.6 million impairment charge on goodwill and other long-lived assets.
For the nine months ended September 30, 2026, Longeveron Inc. reported a net loss of $16.9 million, a slight improvement from the $17.3 million loss in the prior year period. Total revenues decreased slightly to $0.8 million, while the company strengthened its cash position to $7.2 million through private placements and warrant exercises.
Birchtech Corp. reported a net loss of $4.6 million for the nine months ended September 30, 2026, compared to a $2.4 million loss in the prior year period, despite a 23% increase in product revenue. The company significantly strengthened its balance sheet during the period, ending with $10.8 million in cash following a common stock issuance that raised approximately $14.2 million in net proceeds.
Franklin Covey Co. reported fiscal 2026 consolidated revenue of $261.5 million, a 2% decrease from the prior year, while net income improved to $4.9 million. Despite lower revenues in the Enterprise Division due to macroeconomic uncertainties and geopolitical tensions, Adjusted EBITDA increased slightly to $28.9 million, supported by restructuring activities and cost reduction efforts.
Holistic Asset Finance Group Co., Ltd. reported a significant increase in revenue to $4.94 million for the nine months ended September 30, 2026, compared to $1.69 million in the prior year. The company achieved a small net income of $2,436 for the period, recovering from a net loss of $36,331 in 2025, primarily driven by its export trading and marketing services operations.
AnaptysBio reported financial results for the fiscal first quarter ended September 30, 2026, highlighted by $1.0 billion in global net sales of Jemperli for the first nine months of 2026. The company is currently awaiting a court judgment in its litigation against GSK and Tesaro, where it is seeking the reversion of Jemperli rights as a remedy.
Counterparty
GSK
“Jemperli’s continued commercial growth in endometrial cancer, with global net sales reaching $1 billion through September 30, 2026, and its recent U.S. approval in adults with stage II and III MSI-H/dMMR locally advanced rectal cancer reinforce our confidence in its long-term potential in monotherapy indications.”
Daniel Faga, president and chief executive officer
“We remain focused on protecting and returning the value of our financial collaborations to shareholders as we approach a judgment in our litigation with GSK and Tesaro in calendar Q4 2026 or Q1 2027 and the FDA target action date for Quimilza in December 2026.”
Daniel Faga, president and chief executive officer
Polaryx Therapeutics reported a net loss of $7.3 million for the nine months ended September 30, 2026, compared to $7.5 million in the prior year period. The company maintains a going concern warning due to recurring losses and negative operating cash flows, though it successfully raised $9.8 million through common stock issuances during the period.
MultiSensor AI Holdings reported Q3 2026 financial results, highlighted by a 43% increase in software revenue which now represents 58% of total revenue. The company reported a net loss of $1.9 million on total revenue of $1.5 million, while maintaining a debt-free balance sheet with $20.4 million in cash.
Term
Q3 2026
“Our relationship with our largest distribution customer shows how we believe this business scales. Programs that began in Europe continue to grow, with solar performance monitoring now extending to additional European sites, and have led to that customer’s first 14-site rollout in North America. Each step has been built on results their maintenance teams have seen in their own facilities, and we are seeing that same path open up with customers like Manchester Airports Group.”
Asim Akram, Chief Executive Officer
“Our revenue mix is shifting the way we intended. Software subscriptions are now the majority of our revenue for the quarter, and recurring revenue continues to grow, which gives us better visibility into the periods ahead. We paired that with disciplined spending, and with help from strong collections our cash use slowed meaningfully in the third quarter. With no debt, we have the balance sheet to keep investing in recurring revenue.”
Beeline Holdings, Inc. reported a net loss of $13.1 million for the nine months ended September 30, 2026, compared to a $15.0 million loss in the prior year period. Total net revenues grew significantly to $8.3 million from $5.3 million, driven by higher gains on loan sales and origination fees, though operating expenses also increased to $21.8 million.
Marpai, Inc. reported a net loss of $11.1 million for the nine months ended September 30, 2026, with revenue declining to $13.0 million from $14.1 million in the prior year period. The company improved its stockholders' deficit to $29.8 million, aided by the issuance of $12.1 million in privately placed preferred stock.